NEWS

Filter By
For all media inquiries, please contact media@tempus.com
  • 11/20/2023

    Tempus Welcomes City of Hope Comprehensive Cancer Center to Tempus+ Community

    Tempus, a leader in artificial intelligence and precision medicine, today announced that City of Hope Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers represents over 30 medical centers that are leveraging the program to advance...

  • 11/15/2023

    Tempus Announces Medicare Coverage for Tempus xT Across Solid Tumor and Hematologic Malignancies

    Tempus, a leader in artificial intelligence and precision medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies, performed in Tempus’ CAP/CLIA laborator...

  • 11/09/2023

    Tempus Announces New Strategic Collaboration with Recursion to Advance Therapeutic Development

    Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with Recursion (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. The two companies are working together to advance biomarker-driven therapeutic development with a data-first approach.  Through this coll...

  • 11/08/2023

    Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches

    Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE: BMY). The two companies will work together to identify new targets and validate them faster and with higher confidence using multimodal datasets, computational approaches, and patient-derived disease mode...

  • 11/07/2023

    Tempus Welcomes Rush University Medical Center to Tempus+ Community

    Tempus, a leader in artificial intelligence and precision medicine, today announced that Rush University Medical Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers that are leveraging the program to advance its research...

  • Tempus Announces New ctDNA Assay, xM Monitor

    Tumor uninformed treatment response monitoring assay for research use only Tempus, a leader in artificial intelligence and precision medicine, today announced xM Monitor (formerly xF Monitor) – a new circulating tumor DNA (ctDNA) assay for research use only, which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy fo...

  • 11/01/2023

    Tempus Announces Eight Abstracts Accepted For Presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting

    Tempus, a leader in artificial intelligence and precision medicine, today announced eight abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, which convenes in San Diego, California, from November 1-5, 2023.  "We continue to be a leader in the advancement of immunotherapy research, as evidenced...

  • 10/20/2023

    Tempus Announces Five Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2023

    Tempus, a leader in artificial intelligence and precision medicine, today announced five abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2023, which convenes in Madrid, Spain, from October 20-24, 2023.  "We are excited to share our latest research at ESMO this year, as we continue to make our precision medici...

  • 08/22/2023

    Tempus Welcomes UNC Lineberger Comprehensive Cancer Center to Tempus+ Community

    Tempus, a leader in artificial intelligence and precision medicine, today announced that the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers t...

  • 08/15/2023

    FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test

    Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test. The test uses a machine learning model to analyze sequence data produced b...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18